Sanofi SA (EPA:SAN) received a €82.00 ($96.47) price target from stock analysts at Goldman Sachs Group, Inc. (The) in a research note issued to investors on Monday. The brokerage presently has a “neutral” rating on the stock.

Several other equities analysts also recently weighed in on SAN. J P Morgan Chase & Co set a €87.00 ($102.35) price target on shares of Sanofi SA and gave the stock a “neutral” rating in a report on Tuesday, April 11th. Deutsche Bank AG set a €96.00 ($112.94) price target on shares of Sanofi SA and gave the stock a “buy” rating in a report on Tuesday, April 11th. Kepler Capital Markets set a €92.00 ($108.24) price target on shares of Sanofi SA and gave the stock a “buy” rating in a report on Wednesday, April 12th. Morgan Stanley set a €91.00 ($107.06) price target on shares of Sanofi SA and gave the stock a “buy” rating in a report on Monday, April 24th. Finally, Berenberg Bank set a €92.00 ($108.24) price target on shares of Sanofi SA and gave the stock a “buy” rating in a report on Friday, April 28th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of €87.63 ($103.09).

Shares of Sanofi SA (EPA SAN) traded up 0.09% during mid-day trading on Monday, hitting €81.68. 1,635,351 shares of the stock were exchanged. The stock has a 50-day moving average price of €25.48 and a 200 day moving average price of €25.74. Sanofi SA has a 52-week low of €62.50 and a 52-week high of €92.97. The firm has a market cap of €102.57 billion and a price-to-earnings ratio of 11.40.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/07/goldman-sachs-group-inc-the-analysts-give-sanofi-sa-san-a-82-00-price-target.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.